Hernandez I, Gobinath C, Padilla A, Loyola C, Joddar B
Res Sq. 2025; .
PMID: 39764116
PMC: 11702775.
DOI: 10.21203/rs.3.rs-5125697/v1.
Polepalle T, Mannava P, Pesala D, Sharma R, Elango A, Ghate S
J Pharm Bioallied Sci. 2024; 16(Suppl 3):S2300-S2302.
PMID: 39346331
PMC: 11426738.
DOI: 10.4103/jpbs.jpbs_208_24.
Lee H, Gu M, Yoo G, Choi I, Lee S, Kim Y
PLoS One. 2022; 17(7):e0270249.
PMID: 35788200
PMC: 9255721.
DOI: 10.1371/journal.pone.0270249.
Logette E, Lorin C, Favreau C, Oshurko E, Coggan J, Casalegno F
Front Public Health. 2021; 9:695139.
PMID: 34395368
PMC: 8356061.
DOI: 10.3389/fpubh.2021.695139.
Dec-Gilowska M, Trojnar M, Makaruk B, Mosiewicz-Madejska B, Dzida G, Mosiewicz J
J Int Med Res. 2020; 48(9):300060520952643.
PMID: 32909478
PMC: 7488900.
DOI: 10.1177/0300060520952643.
The Role of Nonenzymatic Post-translational Protein Modifications in Uremic Vascular Calcification.
Lim K, Kalim S
Adv Chronic Kidney Dis. 2019; 26(6):427-436.
PMID: 31831121
PMC: 6993873.
DOI: 10.1053/j.ackd.2019.10.001.
Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification.
Prasad C, Davis K, Imrhan V, Juma S, Vijayagopal P
Am J Lifestyle Med. 2019; 13(4):384-404.
PMID: 31285723
PMC: 6600625.
DOI: 10.1177/1559827617708991.
The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review.
Fishman S, Sonmez H, Basman C, Singh V, Poretsky L
Mol Med. 2018; 24(1):59.
PMID: 30470170
PMC: 6251169.
DOI: 10.1186/s10020-018-0060-3.
Evaluation of the Antioxidant and Antiglycation Effects of and Extracts on Hepatorenal Injury in Streptozotocin-Induced Diabetic Rats.
Arambasic Jovanovic J, Mihailovic M, Uskokovic A, Grdovic N, Dinic S, Poznanovic G
Front Pharmacol. 2017; 8:793.
PMID: 29163175
PMC: 5671656.
DOI: 10.3389/fphar.2017.00793.
Role of RAGE in Alzheimer's Disease.
Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M
Cell Mol Neurobiol. 2015; 36(4):483-95.
PMID: 26175217
PMC: 11482350.
DOI: 10.1007/s10571-015-0233-3.
Advanced glycation end products and diabetic retinopathy.
Sharma Y, Saxena S, Mishra A, Saxena A, Natu S
J Ocul Biol Dis Infor. 2014; 5(3-4):63-9.
PMID: 24596941
PMC: 3709028.
DOI: 10.1007/s12177-013-9104-7.
Platelet function profiles in patients with diabetes mellitus.
Rollini F, Franchi F, Muniz-Lozano A, Angiolillo D
J Cardiovasc Transl Res. 2013; 6(3):329-45.
PMID: 23404189
DOI: 10.1007/s12265-013-9449-0.
Beneficial effect of traditional chinese medicinal formula danggui-shaoyao-san on advanced glycation end-product-mediated renal injury in streptozotocin-diabetic rats.
Liu I, Tzeng T, Liou S, Chang C
Evid Based Complement Alternat Med. 2011; 2012:140103.
PMID: 21837246
PMC: 3151508.
DOI: 10.1155/2012/140103.
Enhanced angiotensin II-mediated central sympathoexcitation in streptozotocin-induced diabetes: role of superoxide anion.
Patel K, Mayhan W, Bidasee K, Zheng H
Am J Physiol Regul Integr Comp Physiol. 2010; 300(2):R311-20.
PMID: 21084672
PMC: 3051357.
DOI: 10.1152/ajpregu.00246.2010.
Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.
Voulgari C, Papadogiannis D, Tentolouris N
Vasc Health Risk Manag. 2010; 6:883-903.
PMID: 21057575
PMC: 2964943.
DOI: 10.2147/VHRM.S11681.
Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis.
Sternberg Z, Hennies C, Sternberg D, Wang P, Kinkel P, Hojnacki D
J Neuroinflammation. 2010; 7:72.
PMID: 21034482
PMC: 2984414.
DOI: 10.1186/1742-2094-7-72.
Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases.
Mendez J, Xie J, Aguilar-Hernandez M, Mendez-Valenzuela V
Mol Cell Biochem. 2010; 344(1-2):185-93.
PMID: 20680411
DOI: 10.1007/s11010-010-0541-3.
Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy.
Yoon Y, Kang T, Lee B, Chang W, Hwang K, Rhee J
Exp Mol Med. 2008; 40(4):398-406.
PMID: 18779652
PMC: 2679265.
DOI: 10.3858/emm.2008.40.4.398.
Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus.
Tentolouris N, Papazafiropoulou A, Moyssakis I, Liatis S, Perrea D, Kostakis M
Cardiovasc Diabetol. 2008; 7:1.
PMID: 18171473
PMC: 2235836.
DOI: 10.1186/1475-2840-7-1.
Venous or arterial endothelium evaluation for early cardiovascular dysfunction in hypertensive patients?.
Rubira M, Consolim-Colombo F, Rabelo E, Yugar-Toledo J, Casarini D, Coimbra S
J Clin Hypertens (Greenwich). 2007; 9(11):859-65.
PMID: 17978593
PMC: 8109986.
DOI: 10.1111/j.1524-6175.2007.06643.x.